MedPath

Safety of Latanoprost Eyedrops

Not Applicable
Conditions
Health Condition 1: H409- Unspecified glaucoma
Registration Number
CTRI/2021/10/037348
Lead Sponsor
Aravind Eye Hospital Pondicherry
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients using Latanoprost eyedrops

Exclusion Criteria

Patients using glaucoma eyedrops other than Latanoprost

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the concentration of the eyedrops at the end of 4 and 6 weeks after opening the eye bottle as compared to the baselineTimepoint: 4 and 6 weeks
Secondary Outcome Measures
NameTimeMethod
To assess the contamination levels at 4 and 6 weeksTimepoint: 4 and 6 weeks
© Copyright 2025. All Rights Reserved by MedPath